Objective. Depression during pregnancy is a relatively common problem. Since little is known about the teratogenic effects of\r\nconcomitant administration of fluoxetine and olanzapine during the organogenesis period, the aim of the present study was to\r\nevaluate the teratogenic effects of coadministration of fluoxetine and olanzapine on rat fetuses. Method. Forty-two pregnant rats\r\nwere divided into seven groups, randomly. The first group received 0.5mL of normal saline as the control. The second and third\r\ngroups received fluoxetine at doses of 9mg/kg and 18mg/kg, respectively. Olanzapine was injected at 3mg/kg and 6mg/kg to the\r\nfourth and fifth groups, respectively.The sixth group received 9mg/kg fluoxetine and 3mg/kg olanzapine. Finally, the seventh group\r\nwas administrated with fluoxetine and olanzapine at 18mg/kg and 6mg/kg, respectively. Drugs were injected intraperitoneally\r\nbetween day eight and day 15 of the pregnancy.On the 17th day of pregnancy, the fetuses were removed and micro-/macroscopically\r\nstudied. Results. Fetuses of rats receiving high doses of these drugs showed a significant rate of cleft palate development, premature\r\neyelid opening and torsion anomalies, compared to the control group (?? = 0.01). It is concluded that these drugs can lead to\r\nteratogenicity, so their concomitant use during pregnancy should be avoided, or if necessary their doses must be decreased.
Loading....